tiprankstipranks
Bone Biologics Corp. (BBLG)
NASDAQ:BBLG
US Market
Holding BBLG?
Track your performance easily

Bone Biologics (BBLG) Income Statement

61 Followers

Bone Biologics Income Statement

Last quarter (Q ), Bone Biologics's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Bone Biologics's net income was $-783.73K. See Bone Biologics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 3.15M$ 9.43M$ 3.67M$ 1.10M$ 825.01K$ 2.45M
Operating Income
$ -4.95M$ -9.43M$ -3.67M$ -1.10M$ -825.01K$ -2.45M
Net Non Operating Interest Income Expense
$ 16.29K$ 1.87K$ 731.71K$ -805.11K$ -998.08K$ -975.77K
Other Income Expense
$ 1.14M$ 477.70K$ 2.91M$ -297.50K--
Pretax Income
$ -3.31M$ -8.95M$ -1.48M$ -1.61M$ -1.82M$ -3.42M
Tax Provision
---$ 1.60K$ 1.60K$ 1.60K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -5.15M$ -8.95M$ -1.48M$ -1.61M$ -1.82M$ -3.42M
Basic EPS
$ 24.42$ -34.01$ -31.20$ -84.00$ -60.00-
Diluted EPS
$ 24.42$ -34.01$ -31.20$ -84.00$ -60.00$ -1.17
Basic Average Shares
$ 2.68M$ 263.14K$ 47.58K$ 18.92K$ 30.33K$ 2.92M
Diluted Average Shares
$ 2.68M$ 263.14K$ 47.58K$ 18.92K$ 30.33K$ 2.92M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 3.15M$ 9.43M$ 3.67M$ 1.10M$ 825.01K$ 2.45M
Net Income From Continuing And Discontinued Operation
$ -5.15M$ -8.95M$ -1.48M$ -1.61M$ -1.82M$ -3.42M
Normalized Income
$ -2.00M$ -7.07M----
Interest Expense
------
EBIT
$ -3.08M$ -9.43M$ -3.67M$ -805.58K$ -825.01K$ -2.45M
EBITDA
$ -3.08M$ -9.43M$ -3.67M$ -805.58K$ -825.01K$ -2.45M
Currency in USD

Bone Biologics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis